Dosing
Microdosing means taking less than the label says and staying there. No regulator recognises the term and no randomised trial has tested it, so every claim about how well it works is extrapolated from data collected at higher doses. These seven pages set out the approved schedules, the trial numbers with the week and the dose attached, and the risks that a smaller dose does not change.
The term explained honestly: no regulator uses it, no trial tested it, and every dose-response curve in the field runs the other way.
The label ladder laid next to the STEP programme, so you can see exactly how far a microdose sits from anything that was measured.
Tirzepatide has the only published maintenance dose-response curve in the field, and a microdose sits below the bottom of it.
The reference table: what each label says, next to what each trial measured, with no microdose column because no product has one.
The four axes people are really weighing, and which of them have evidence at a low dose. Two do, one does not.
The strongest legitimate case for low-dose GLP-1, and the specific trial that has never been run.
Which adverse effects actually track with dose, and which categories a lower dose changes nothing about.
Evidence updates
Approvals move, trials read out, labels get rewritten. We re-check these pages against their primary sources and email what actually changed, with the citation next to it.
What you will not get: protocols, supplement offers, "wellness" or a drip sequence. If a month goes by and nothing worth sending has changed, we do not send anything.
Confirmed by email before anything is sent, so a typo cannot sign up a stranger. One-click unsubscribe in every message. The list is never shared or sold.